Author

Duygu Duzgun

University of Exeter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioinformatics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Approach:benchmark study· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

Sebastian OlteaniD· 3 shared Holly RusselliD· 1 shared Jinxia ZhengiD· 1 shared Ling LiiD· 1 shared William Read· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

5 top collaborators · 7 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Sebastian OlteanORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer

Duygu Duzgun, William Read, Sebastian Oltean

This study identifies SRPK1 as a key regulator of docetaxel resistance in prostate cancer by modulating splicing and apoptosis pathways.

bioRxiv · Sep 17, 2026 · PreprintCancer Biology

Modulators of epithelial-mesenchymal transitions in prostate cancer: potential for novel therapeutics development

Jinxia Zheng, Ling Li, Holly Russell, Duygu Duzgun, Sebastian Oltean

This study investigates three chemicals (LLSOs) that modulate epithelial-mesenchymal transition in prostate cancer cells, showing inhibition of migration and tumor growth in vivo.

Frontiers in Pharmacology · Aug 18, 2026Peer-reviewedCancer Biology

Clinical Implications of SRPK1 Expression in Human Tumours: A Comprehensive Pan-Cancer Analysis Based on Multi-Omics Databases

Duygu Duzgun, Sebastian Oltean

This study investigates SRPK1 expression across multiple cancer types using multi-omics data, finding its association with poor survival and chemoresistance.

bioRxiv · Nov 25, 2025 · PreprintBioinformatics